Adenoid cystic carcinoma is the most common malignant tumor of salivary gland origin. About 10-25% of head and neck adenoid cystic carcinoma occurs in the nasal cavity and paranasal sinuses. In addition to the characteristics of local invasion and distant metastasis, adenoid cystic carcinoma also has the characteristics of neurophilic growth, and can invade the brain along the peripheral nerve. The 5-year overall survival rate of adenoid cystic carcinoma in nasal cavity and paranasal sinuses was 62%, which was much lower than that of adenoid cystic carcinoma from salivary glands in other parts of head and neck. Surgical resection is the first choice for adenoid cystic carcinoma of the nasal cavity and paranasal sinuses; For advanced adenoid cystic carcinoma of the nasal cavity and paranasal sinuses, especially in patients with orbital or intracranial invasion, radical surgery may cause severe functional loss, and the postoperative local recurrence or distant metastasis rate is still high, so comprehensive treatment based on surgical treatment is needed.
The nasal skull base surgery team has completed more than 6000 cases of nasal endoscopic surgery annually, including more than 1500 cases of nasal skull base tumor surgery, which is at the leading level in the field of endoscopic treatment of nasal skull base tumor both at home and abroad. In view of the fact that adenoid cystic carcinoma in the nasal cavity and paranasal sinuses is easy to invade the retrograde growth of trigeminal nerve branches, the team carried out endoscopic dural dissection technology, which effectively improved the total resection rate of adenoid cystic carcinoma invading the dura mater of middle cranial fossa and Maxwell's cavity; At the same time, the comprehensive treatment of surgery combined with radiotherapy effectively improved the survival rate of patients and quality of life. In the past two years, more than 90 cases of adenoid cystic carcinoma in the nasal cavity and paranasal sinuses have been operated in our hospital. More than 85% of them are stage III-IV patients. The one-year local recurrence free survival rate is comparable to the international level.
Nasal adenoid cystic carcinoma subspecialty in Fudan EENT was officially established in April 2021. Young skull base surgery expert Liu Quan is the head of the subspecialty. Professor Wang Dehui and Professor Yu Hongmeng personally participate in the construction of the subspecialty. The subspecialty will work together with radiotherapy department, imaging department, interventional department and other departments to develop accurate diagnosis and treatment plan for each patient, To provide diagnosis and treatment scheme in one “package” for comprehensive treatment of patients, so as to further improve the survival rate of patients and quality of life.